Mental Health Clinics in Yuma, CO Accepting Medicare
4 Mental Health Clinics found. Showing 1 - 4
 Centennial Mental Health Center, Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 215 S Ash St, Yuma, CO 80759 Phone: 970-848-5412 |
Pharos Pointe Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 717 S Ash St, Yuma, CO 80759 Phone: 970-630-5863 |
Centennial Mental Health Center Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 215 S Ash St, Yuma, CO 80759 Phone: 970-848-5412 Fax: 970-848-2414 |
Centennial Mental Health Center, Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 215 S Ash St, Yuma, CO 80759 Phone: 970-522-4549 |
News Archive
Cannabis can reduce spasticity in MS patients
Cannabis can reduce spasticity in multiple sclerosis (MS) patients. A systematic review, published in the open access journal BMC Neurology, found that five out six randomized controlled trials reported a reduction in spasticity and an improvement in mobility.
German researchers find way to accurately differentiate prostate cancer from benign tissue
Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine.
Researchers review environmental risk assessments for recombinant COVID-19 viral vector vaccines
In a recent review, published in the journal Vaccines, researchers in Belgium look at the recombinant viral vector-vaccine candidates that are primarily against SARS-CoV-2 still in development and discuss their features from an environmental risk point of view.
High-dose vitamin D recommended for over 65s
Meta-analysis findings support recommendations from the Institute of Medicine that people aged 65 years and older should routinely receive 800 IU of vitamin D per day.
Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada
Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON™), the Company's clinical-stage drug candidate that has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease.
› Verified 9 days ago